Four factors that shape ChondroFiller candidacy

Whether ChondroFiller injection is the right option comes down to four specific factors that a consultant will work through at assessment: the grade of cartilage damage, the size and distribution of the affected area, the mechanical environment of the joint, and the patient's overall health profile. Each carries weight independently — a strong result on three factors can still be undermined by the fourth.

The starting point is always imaging. Two patients with near-identical pain levels may arrive at very different recommendations once MRI has revealed what is actually happening inside the joint. Symptom severity guides urgency; it does not determine suitability.

It is also worth knowing from the outset that the injectable outpatient pathway sets different — and in several respects broader — eligibility thresholds than surgical cartilage repair options do. Being unsuitable for surgery does not automatically rule out ChondroFiller injection. The sections below work through each criterion in turn.

Which cartilage grades qualify

Two grading systems define where ChondroFiller sits on the cartilage damage spectrum, and understanding both helps set realistic expectations before a consultation.

The ICRS scale (also called the Outerbridge scale) scores cartilage on a four-point system based on depth of damage. Grade I and II lesions — surface softening or shallow fissuring — do not meet the threshold for ChondroFiller because the scaffold's mechanism of matrix-induced chondrogenesis requires meaningful structural loss to act on: there must be enough damage for the collagen matrix to do its job of recruiting the body's own repair cells. Grade III, where fissuring or fragmentation extends deeper without yet reaching bone, and Grade IV, where the full cartilage thickness is lost and subchondral bone is exposed, define the formal CE-mark indication.

For osteoarthritis-pattern damage, the equivalent measure is the Kellgren-Lawrence (KL) scale. KL Grade III–IV is the most commonly presenting diagnosis seen in clinical practice, and ChondroFiller injection supports the body's own repair processes across the worn joint surface without restriction by defect size.

At KL Grade IV — diffuse, advanced wear — the clinical goal shifts. Rather than structural regeneration, the scaffold acts as a collagen cushion, offering protective coverage and symptom management. The evidence base for this indication is thinner than for focal defects; it is best understood as an emerging application rather than an established one, and outcome expectations should be discussed openly at consultation.

How defect size affects the injectable pathway

For patients who have been told they are beyond the scope of surgical cartilage repair, the size rules governing the injectable pathway are consequential.

Surgical options such as microfracture are optimised for smaller defects — typically under 2–4 cm² — while autologous chondrocyte implantation (ACI or MACI) suits larger but still well-contained focal areas above that threshold. Both require a defined lesion with healthy surrounding cartilage; when damage is diffuse or multi-focal, neither option is straightforwardly applicable.

The injectable ChondroFiller pathway works differently. Delivered as a liquid collagen scaffold under ultrasound guidance, it can coat the entire articular surface in a single outpatient appointment. There is no published defect-size ceiling for this route: whether the wear is a single contained area or spread across the joint, the scaffold distributes across the available surface and recruits the body's own repair cells through matrix-induced chondrogenesis.

One practical exception applies to the hip. For hip lesions specifically, reliable injectable coverage becomes more difficult above approximately 6 cm² in area — roughly 2.5 cm in diameter. Beyond that threshold, consistent filling is harder to achieve and the case for endogenous repair weakens accordingly.

For the knee, shoulder, ankle, and other joints, diffuse or multi-focal wear patterns that fall outside surgical eligibility remain within reach of the outpatient injectable route — a clinically important distinction for patients who assumed their options were limited.

Why joint alignment is a prerequisite, not an afterthought

Cartilage grade and defect size matter considerably, but neither factor overrides the most fundamental question in candidacy: is the joint mechanically stable?

The collagen scaffold repairs a damaged surface — it cannot protect that surface from forces that are continuously re-damaging it. Untreated ligament instability, significant joint malalignment, and meniscal deficits actively driving further wear will all undermine repair regardless of how well the injection is placed. If the mechanical cause of the damage remains unaddressed, the scaffold is unlikely to hold.

In the hip, femoroacetabular impingement (FAI) is the most commonly cited example. Where FAI is identified, the abnormal contact between the femoral head and acetabulum must be managed concurrently — leaving it in place directly compromises any cartilage repair attempt.

Active inflammatory arthritis — rheumatoid arthritis being the clearest example — is a contraindication for a different reason. Matrix-induced chondrogenesis depends on a biological environment that supports cell recruitment and scaffold integration; active synovial inflammation is incompatible with that process.

Correctable mechanical problems do not automatically rule out ChondroFiller. Where instability or malalignment can be managed, staged or concurrent treatment may restore candidacy. Whether that applies in a specific case is a question for specialist assessment — the decision hinges on what the imaging and clinical examination together reveal.

The typical ChondroFiller patient

Age is perhaps the most persistent misconception about ChondroFiller candidacy: there is no published upper limit. Clinical sources describe the injectable pathway as particularly well-suited to active patients in their 60s, 70s, and beyond — people who want to continue walking, cycling, or playing sport without committing to joint replacement ahead of schedule.

The patient who typically arrives at assessment has been working through conservative management for some time. Physiotherapy, analgesics, and activity modifications may have steadied things but have not resolved the underlying structural problem that MRI has since confirmed. Imaging matters here because structural damage and symptom severity do not always move in step — a patient with Grade IV cartilage loss may report less pain on a given day than someone with Grade III, depending on loading patterns and individual pain threshold. The scan reveals what the pain score cannot.

Presenting diagnoses span a range of origins. Post-traumatic chondral lesions — from a collision, fall, or twisting injury — are a frequent route in. Osteochondritis dissecans (OCD), in which a fragment of cartilage and its underlying subchondral bone partially separates from the joint surface, is another well-recognised presentation. Cartilage damage that has accumulated after a meniscal tear or following ligament reconstruction is a third common pathway: once the joint's natural protective architecture is disturbed, wear tends to concentrate at predictable sites. In each scenario, what the consultant is establishing from the MRI is whether the damage has reached the structural threshold — ICRS Grade III or IV — at which the ChondroFiller scaffold can meaningfully support the body's own repair processes through matrix-induced chondrogenesis.

Starting the assessment: what to expect

The assessment itself is where candidacy becomes concrete. A specialist cartilage consultation brings together MRI review, clinical examination, and a discussion of realistic treatment goals — before any pathway decision is reached. Symptom scores and GP referral letters are a starting point, not a verdict: two patients describing identical pain may leave with very different recommendations depending on what the imaging shows about cartilage grade, defect distribution, and the mechanical state of the joint.

What that process ultimately establishes is something the pain score alone cannot: whether the structural findings and joint environment together make ChondroFiller injection appropriate. The realistic candidate is not defined by age or how long symptoms have been present, but by what the MRI reveals and whether the mechanical conditions can support repair — a judgement that requires a specialist's eye on the scan, not a symptom questionnaire.

London Cartilage Clinic, based on Harley Street, offers specialist assessment for ChondroFiller candidacy as part of its cartilage and joint-preservation service. To find out whether ChondroFiller injection is the right option for your joint, book a consultation at londoncartilage.com.